E. Ohman J:or Asset Management’s 10x Genomics TXG Stock Holding History

E. Ohman J:or Asset Management’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-86,086	Closed	-$2.45M	–	446
2022 Q3	$2.45M	Sell	86,086 -1,914	-2%	-$72.9K	0.11%	113
2022 Q2	$3.98M	Sell	88,000 -12,000	-12%	-$623K	0.17%	79
2022 Q1	$7.61M	Buy	+100,000	New	+$8.75M	0.25%	68
2021 Q4	–	Sell	-4,000	Closed	-$582K	–	500
2021 Q3	$582K	Buy	+4,000	New	+$687K	0.02%	373

Other funds holding TXG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SIM

SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

E. Ohman J:or Asset Management's TXG Position: Q4 2022 in Review

E. Ohman J:or Asset Management sold out of 10x Genomics (TXG) in Q4 2022, closing a stake of 86,086 shares — an estimated $2.45M sold.

E. Ohman J:or Asset Management first reported a position in TXG in Q3 2021 and held it in 4 quarters. The position peaked at $7.61M in Q1 2022. 268 funds tracked by Wall St. Rank hold TXG as of Q4 2022.

E. Ohman J:or Asset Management reported no remaining 10x Genomics position as of Q4 2022 after selling out during the quarter.
E. Ohman J:or Asset Management sold 86,086 10x Genomics shares in Q4 2022, an estimated $2.45M.
E. Ohman J:or Asset Management first reported a position in 10x Genomics in Q3 2021 and held it in 4 quarters.
E. Ohman J:or Asset Management's 10x Genomics position peaked at $7.61M in Q1 2022.
268 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2022.

Based on E. Ohman J:or Asset Management's 13F filing for Q4 2022, filed 5 Apr 2024.